26 C
Vientiane
Wednesday, July 2, 2025
spot_img
Home Blog Page 1212

Fostering Indigenous Language-Friendly Environments! United for the Preservation of Austronesian Languages in Kaohsiung City, Taiwan


TAIPEI, TAIWAN – Media OutReach Newswire – 12 November 2024 – The 2024 Austronesian Languages Revitalization Forum, organized by Taiwan’s Indigenous Languages Research and Development Foundation (ILRDF), centers on the theme of “Building Indigenous Language-Friendly Environments.” At the forum, representatives from various countries discussed strategies and measures to promote indigenous language-friendly environments, enhance language education, and encourage community involvement, all with the goal of raising societal awareness of indigenous languages and Austronesian cultures. Chairman Mayaw·Kumud of the ILRDF highlighted that the Austronesian languages spoken by the indigenous peoples in Taiwan and across the Pacific boast rich cultural resources. However, many of these Austronesian languages are struggling with a gradual death in the face of globalization and modernization.

Chairman Mayaw·Kumud of the Indigenous Languages Research and Development Foundation of Taiwan delivered his remarks.
Chairman Mayaw·Kumud of the Indigenous Languages Research and Development Foundation of Taiwan delivered his remarks.

This forum reflects a deep commitment to the sustainable development of Austronesian languages and cultures. Through international exchange, delegates, experts, and scholars from around the world shared successful experiences and explored effective language revitalization strategies. In addition, many participants delivered their speeches in their native languages. Meanwhile, to ensure understanding among those from different linguistic backgrounds, ILRDF arranged for simultaneous interpretation and live-streaming services in seven languages: Mandarin, English, Amis, Paiwan, Atayal, Bunun, and Sediq. This fully demonstrated the linguistic diversity and autonomy of Austronesian languages.

During the forum, local scholars and international experts, including members from New Zealand’s Te Mātāwai, an organization for Maori language revitalization, discussed strategies and measures for fostering indigenous language-friendly environments. The dialogue fostered connections and exchanges across islands. Furthermore, as the forum amplifies the influence of Austronesian languages, domestic and international partnerships are established to jointly promote language preservation and transmission.

Hashtag: #ILRDF

The issuer is solely responsible for the content of this announcement.

U.S. Election Shakes the Ringgit: Octa Broker’s Analysis


KUALA LUMPUR, MALAYSIA – Media OutReach Newswire – 12 November 2024 – The recent U.S. presidential election and subsequent economic events have significantly impacted the Malaysian Ringgit (MYR), with the USDMYR exchange rate reaching a three-month high on Monday. Octa Broker’s financial market analyst, Kar Yong Ang, explains the reasons for the recent weakness in the Malaysian ringgit and provides short-term exchange rate projections.

U.S. Election Shakes the Ringgit: Octa Broker's Analysis

It has been a very tough week for the Malaysian ringgit as three major events—the U.S. presidential elections, the Federal Reserve (Fed) meeting, and the Bank Negara Malaysia (BNM) rate decision—were in the spotlight. Arguably, the most significant event was the election of Donald Trump as the next president of the United States. The U.S. dollar rallied across the board, pushing other major currencies down. Asian currencies were no exception, with Malaysian ringgit (MYR) losing some 1.4% in value on 6 November. The U.S. Dollar Index (DXY), which measures the strength of the U.S. dollar against a weighted basket of six major foreign currencies, gained 1.64% on that day. ‘Such a dramatic rise in the greenback’s value is explained by Trump’s official policies, or more precisely by the implied effect these policies are likely to have,’ says Kar Yong Ang, a financial market analyst at Octa Broker. ‘Generally, it all boils down to Trump’s tax, immigration, and trade policies, which differ greatly from what Harris proposed. The market perceives them as inflationary, which is why we saw a bullish impact in the U.S. dollar.’

Indeed, mass deportations of illegal immigrants may put upward pressure on wages, while introducing new tariffs may increase import costs. If, under these circumstances, U.S. nationwide inflation accelerates, the Fed will be forced to pursue a tighter monetary policy and keep the interest rates higher for longer. Although last Thursday, the Fed did cut the rates by 25 basis points (bps), as the market expected, Jerome Powell, the Fed’s chair, stressed that further steps would be more cautious and patient. ‘It remains to be seen whether Trump’s policies will have a long-term inflationary impact, but in any case, they will have no near-term impact on the U.S. monetary policy’, says Kar Yong Ang, a financial market analyst at Octa Broker.

Still, Trump’s trade policies carry a major risk for the Malaysian economy in the long term. Malaysia is an export-oriented economy with close links with both China and the United States. Trump’s proposal to introduce broad-based tariffs of 10–20% on all imports arriving in the country and a 60% tariff on Chinese goods would have a major negative impact on Malaysian economic growth. ‘Malaysia is an open economy and has a lot to lose if the U.S. turns protectionist and starts to engage in another trade war with China’, says Kar Yong Ang, a financial market analyst at Octa Broker. Indeed, World Bank estimates that approximately 40% of Malaysian jobs are linked to export activities. New tariffs will act as an external shock hitting the demand for Malaysian goods, slowing down its economy and potentially leading BNM to cut borrowing costs, which, in turn, may put additional upward pressure on USDMYR in the long term. ‘In the worst-case scenario of an all-out trade war between China and the U.S. and a 20% additional tariff on all Malaysian exports into the U.S., USDMYR can rise above the 4.800 level and may hit a critical 5.000 mark. However, I do not see that scenario happening, at least not in the short term’, says Kar Yong Ang, a financial market analyst at Octa Broker.

As things currently stand, the Malaysian economy is on a sound footing. Although the latest macroeconomic statistics have been somewhat disappointing—notably, the annual growth in industrial output slowed in September to 2.3% (vs 3.7% expected by the market), while exports declined by 0.3% (whereas the market expected to see a growth of 7.6%), the general trend is still relatively positive. Official estimates show that gross domestic product (GDP) likely expanded at a solid 5.3% rate in Q3. Although economic growth has slowed from the 5.9% growth rate recorded in Q2, it is still expanding at an impressive rate. Furthermore, as Kar Yong Ang notes: ‘the growth rate in Q2 was actually a bit of an outlier as it was the fastest rate in 18 months, due to exceptionally robust investment and higher household spending and exports’.

U.S. Election Shakes the Ringgit: Octa Broker's Analysis.

A healthy economic outlook is the primary reason why BNM decided to keep its key policy rate unchanged at 3% for the ninth consecutive time last Wednesday even though the annual inflation rate has now dropped to just 1.8%. In its post-meeting statement, Malaysia’s central bank cited a positive economic growth outlook and steady inflation but issued a warning about potential currency volatility. ‘The latest indicators point towards sustained strength in economic activity driven by resilient domestic expenditure and higher export activity’, it said in a statement.

Kar Yong Ang, a financial market analyst at Octa Broker, had this to say: ‘While BNM doesn’t prioritize currency stability, the prevailing financial market uncertainty has prompted the central bank to adopt a cautious approach. For instance, the bank acknowledged that the outcome of the U.S. elections could introduce increased volatility to the ringgit in the short term. However, I personally believe that USDMYR is unlikely to rise much above 4.50 as the narrowing interest rate differential between the U.S. and Malaysia remains a positive factor for the national currency’.Hashtag: #Octa

The issuer is solely responsible for the content of this announcement.

Octa

is an international broker that has been providing online trading services worldwide since 2011. It offers commission-free access to financial markets and various services used by clients from 180 countries who have opened more than 52 million trading accounts. To help its clients reach their investment goals, Octa offers free educational webinars, articles, and analytical tools.

The company is involved in a comprehensive network of charitable and humanitarian initiatives, including the improvement of educational infrastructure and short-notice relief projects supporting local communities.

In the APAC region, Octa received the ‘Best Trading Platform Malaysia 2024’ and the ‘Most Reliable Broker Asia 2023’ awards from Brands and Business Magazine and International Global Forex Awards, respectively.

VinFast secures funding from Vingroup and Pham Nhat Vuong to build financial reserves and accelerate growth


HANOI, VIETNAM – Media OutReach Newswire – 12 November 2024 – On 12 November 2024, Vingroup, Vietnam’s largest private conglomerate, and its Chairman, Mr. Pham Nhat Vuong, announced a significant financial commitment to VinFast, the Vietnamese Nasdaq-listed electric vehicle maker. Vingroup plans to lend VinFast up to 35 trillion Vietnamese dong ($1.4 billion) by the end of 2026. Additionally, Mr. Vuong has personally pledged 50 trillion dong ($2.1 billion) in sponsorship. In a separate move, Vingroup will convert all existing loans, about 80 trillion dong ($3.3 billion), to VinFast Vietnam into dividend-entitled preferred shares.

VinFast has recently become the top-selling automotive brand in Vietnam and has achieved positive impressive results globally, affirming its potential and promising prospects for future growth.
VinFast has recently become the top-selling automotive brand in Vietnam and has achieved positive impressive results globally, affirming its potential and promising prospects for future growth.

The support plan is designed to provide VinFast with sufficient financial resources to fund operations, investments, and other obligations. The goal is to achieve the break-even point and cash flow balance by the end of 2026. However, VinFast remains committed to independently raising capital to meet its financial needs. The support from Vingroup and Mr. Vuong will be utilized only if these independent efforts do not reach the expectation.

VinFast has concluded its initial investment phase, which includes the operation of a 300,000-vehicle-per-year manufacturing plant in Cat Hai, Hai Phong. The Company has also completed research and development of its product line, and is shifting its distribution model from direct-to-consumer to dealership model. VinFast is now in its growth phase, focused on boosting sales across all markets and optimizing its cost structure.

Vingroup’s support agreement is based on a careful assessment of the potential impact on its cash flow and profitability. The goal is to maintain a balance between supporting VinFast and sustaining Vingroup’s own financial health. Once VinFast achieves profitability and financial independence, Vingroup expects to benefit from its investments.

By converting loans to VinFast totaling about 80 trillion dong into preferred equity shares of VinFast Vietnam, Vingroup aims to alleviate short-term financial pressure on the electric vehicle maker. This move will allow Vingroup to maintain its stake in VinFast through dividend rights and the option to convert preferred shares into common shares of VinFast Vietnam Manufacturing and Trading Company or interests in VinFast Singapore.

The new loan of up to 35 trillion Vietnamese dong will be funded through the Vingroup’s business activities, dividends from subsidiaries, and, if necessary, the strategic divestment of certain investments and subsidiaries at a fair market value.

Mr. Pham Nhat Vuong, as VinFast’s CEO and major shareholder, will personally sponsor 50 trillion Vietnamese dong. This personal commitment will not impact the interests of Vingroup or its shareholders.

A representative from Mr. Pham Nhat Vuong's office stated that the newly added financial support ensures sustainable and robust development for VinFast.
A representative from Mr. Pham Nhat Vuong’s office stated that the newly added financial support ensures sustainable and robust development for VinFast.

This support decision was made in light of VinFast recently becoming the top-selling automotive brand in Vietnam and achieving positive results in the global market, affirming its potential for future growth.

In Vietnam market, VinFast has delivered over 51,000 electric vehicles in the first ten months of the year. This achievement marks a significant milestone, as VinFast has surpassed foreign automakers and become the first electric vehicle manufacturer to outsell traditional gasoline-powered vehicles in the country after just over two years of transitioning to an all-electric lineup. Internationally, VinFast continues to expand its business in the U.S., Canada, and Europe, while rapidly penetrating new markets such as the Middle East, Indonesia, the Philippines, and India.

Mr. Nguyen Viet Quang, Vice Chairman of the Board of Directors and CEO of Vingroup, shared: “Vingroup is unwavering in our commitment to a sustainable future. This green vision guides every aspect of our operations. VinFast’s ascent to the top of Vietnam’s automotive market is a testament to our capabilities. This milestone propels us forward, fueling our ambition to accelerate growth. To realize our vision of smart, eco-friendly electric vehicles, Vingroup will continue to invest significantly in VinFast. Our goal is to solidify VinFast’s market leadership in Vietnam and contribute to the global shift towards electric mobility.”

A representative of Mr. Pham Nhat Vuong’s Office said: “With the passion to create a world-class Vietnamese electric car brand, Mr. Pham Nhat Vuong will allocate significant resources to propel VinFast’s advancement. The newly secured funding source provides VinFast with the necessary financial resources to achieve sustainable growth without relying on external capital. This strategic move enables VinFast to prioritize research and development, production, and business expansion.

With Vingroup and Mr. Pham Nhat Vuong as major shareholders and surging customer demand, VinFast is well-positioned to scale up production, optimize costs, and expand its market reach. This will solidify its business capabilities and attract additional investment, accelerating the transition to electric vehicles and making them accessible to a wider audience. VinFast currently offers 7 electric car models in Vietnam from mini-SUV to E-SUV, catering to various segments and budgets.

Hashtag: #VinFast #EVs #VF3 #VF5 #topmarket

The issuer is solely responsible for the content of this announcement.

About VinFast

VinFast (NASDAQ: VFS), a subsidiary of Vingroup JSC, one of Vietnam’s largest conglomerates, is a pure-play EV manufacturer with the mission of making EVs accessible to everyone. VinFast’s product lineup today includes a wide range of electric SUVs, e-scooters, and e-buses. VinFast is currently embarking on its next growth phase through rapid expansion of its distribution and dealership network globally and increasing its manufacturing capacities with a focus on key markets across North America, EMEA and Asia. Learn more at:

The Happi Loft Hosts Christmas Charity Celebration to Spread Holiday Cheer to Underprivileged Children

Partnering with Local Shelters, The Happi Loft Brings Festive Cheer with Personalised Gifts, Holiday Crafts, and Cookie Decorating Activities

SINGAPORE – Media OutReach Newswire – 12 November 2024 – This December, The Happi Loft, a premier event space known for its welcoming ambiance and community-centred events, will transform into a festive winter wonderland for a special Christmas Charity Celebration on December 23, 2024. Designed to bring holiday cheer to children who may not otherwise have the opportunity to celebrate, this event is made possible through a unique partnership with local shelters and businesses, all coming together to make the season brighter for underprivileged children.

The Christmas Charity Celebration promises an unforgettable day filled with holiday-themed activities, games, and festive treats. Local businesses have generously donated gifts, decorations, and holiday snacks to ensure that each child can experience the magic of the season. Children will have the opportunity to decorate holiday cookies, create crafts, and enjoy a visit from Santa Claus, who will be distributing personalised gifts to each child in attendance.

“We are thrilled to bring the community together in such a meaningful way,” said Herron Ho, Co-Founder. “The holiday season is a time for joy, and this event allows us to extend that joy to children who may not otherwise have a Christmas celebration. At The Happi Loft, we are committed to fostering a spirit of giving and inclusivity, and we’re honoured to provide a space where the community can come together for such a wonderful cause.”

In addition to supporting an important initiative, attendees will have the opportunity to tour The Happi Loft’s 2,000 square foot event space, a versatile venue known for its floor-to-ceiling windows, minimalist design, and welcoming atmosphere. Ideal for family gatherings, corporate events, and holiday parties, The Happi Loft will make every event a truly memorable celebration.

The Happi Loft invites community members and families to join in the celebration, help spread holiday cheer, and learn more about the impact of supporting local children’s organisations.

Hashtag: #HappiLoft

The issuer is solely responsible for the content of this announcement.

The Happi Loft

Located in the heart of Singapore, The Happi Loft offers a spacious, 2,000 square foot venue perfect for hosting a wide range of events, including birthdays, corporate events, workshops, and holiday gatherings. With its floor-to-ceiling windows and modern, minimalist design, The Happi Loft is designed to allow for maximum personalisation, creating a memorable experience for each client. Known for exceptional amenities and a dedicated event planning team, The Happi Loft provides seamless support and coordination services to ensure every event is a success. As a hub for community and celebration, The Happi Loft has become the go-to choice for elegant, affordable, and flexible event space in Singapore.

Immuno Cure Biotech Presents Promising Results on Phase I Clinical Trial of a Therapeutic HIV DNA Vaccine

Encouraging findings with immunotherapy aiming at ART-free virological control A significant step towards functional cure of HIV infection


HONG KONG SAR – Media OutReach Newswire – 12 November 2024 – Immuno Cure BioTech (“Immuno Cure“), a clinical-stage biotechnology group based in Hong Kong Science Park, is pleased to announce the completion of a first-in-human novel therapeutic HIV vaccine, ICVAX, Phase I clinical trial with encouraging findings of exceptional safety and promising immunogenicity profiles. This represents a significant step of ICVAX towards achieving antiretroviral therapy (“ART“) free virological control by ICVAX and ultimately accomplishing as a functional cure of HIV/AIDS.

ICVAX is the result of the collaboration between Immuno Cure and Hong Kong AIDS Foundation, HKU AIDS Institute, Hong Kong Science & Technology Parks Corporation and the Shenzhen Third People’s Hospital.
ICVAX is the result of the collaboration between Immuno Cure and Hong Kong AIDS Foundation, HKU AIDS Institute, Hong Kong Science & Technology Parks Corporation and the Shenzhen Third People’s Hospital.

Globally, there are more than 39 million people living with HIV (“PLWH“) and over 40 million deaths since HIV was discovered in 1981. The currently available ART, while highly efficacious, does not cure HIV/AIDS, highlighting the need for an effective immunotherapy to assist ART. Such immunotherapy can potentiate host immune response, aiming to achieve a state of ART-free virological control, and ultimately a complete suppression of virus to an undetectable level in blood for a prolonged period of time, and hence achieving functional cure. Immuno Cure’s ICVAX aims to induce broadly reactive polyfunctional viral-specific T cells to achieve sustained HIV-1 virological control in the absence of ART.

This Phase I clinical trial is a randomized, double-blinded, placebo-controlled, dose-escalation study, approved by the National Medical Products Administration (“NMPA“) and carried out at The Shenzhen Third People’s Hospital (“Shenzhen Third Hospital“), for the evaluation of the safety, maximal tolerating doses, and for the exploration of immunogenicity of ICVAX in clinically stable HIV-1-infected patients whose virus replication are well-suppressed by antiretroviral therapy (clinicaltrials.gov no. NCT06253533), (“Phase I Trial“). A total of 45 participants were recruited and randomly assigned into three dosing groups (1 mg, 2 mg, and 4 mg groups), with an ICVAX-to-placebo ratio of 12:3 in each cohort. ICVAX was delivered by electroporation using Immuno Cure’s NMPA-approved Class II Teresa EP device (“Teresa EP“).

All trial data were reviewed by the Data Safety Monitoring Board (“DSMB”) and unblinded in late September 2024. ICVAX was well tolerated and had a favorable safety profile at all doses studied. All 45 participants completed the scheduled visits. All reported treatment-related adverse events were mild, and no treatment-related severe adverse events were reported. Overall, ICVAX vaccine recipients demonstrated promising T cell responses. In those receiving the optimal ICVAX dose, a large majority had more than 2-fold increase in T cell responses. Critically, ICVAX could enhance functional T cells previously found in Elite Controllers (“EC“) for HIV-1 control. The primary and secondary endpoints of the Phase I trial have been met. Immuno Cure plans to share such promising findings from the Phase I Trial in scientific conferences and in a peer-reviewed scientific journal. The Phase I Trial data will be submitted to regulatory agencies for review for advancing the vaccine into a Phase II efficacy clinical trial.

Dr. Hongzhou LU MD, PhD, President of Shenzhen Third Hospital and Co-Principal Investigator of the Phase I Trial, said “We are incredibly excited with these unprecedented results of the Phase I clinical trial of ICVAX upon unblinding after thorough review and clearance by the DSMB. These promising trial data laid a solid foundation for the upcoming Phase II clinical trial, and for ICVAX to ultimately achieve ART-free virological control in HIV-1 patients and potentially the long-awaited functional cure of HIV/AIDS for PLWH. We thank the volunteers for their selfless participation and commitment to finish the entire trial. I believe many patients are eager to join the next stage of clinical trials of the candidate HIV vaccine.”

HKU AIDS Institute has been leading a collaborative research initiative in association with Immuno Cure and other academic institutions on ICVAX, which was awarded significant grant funding twice under the Theme-based Research Scheme (“TRS“) from the Research Grants Council (“RGC“), aggregating to some HK$ 113.8 million. In the first 5-year term of TRS 18/19 (8th round), HK$47.1 million was granted for basic research of ICVAX, studying PD-1-Enhanced DNA vaccine-based combination immunotherapy in monkey models and human subjects. Recently, in the second 5-year term of TRS 24/25 (14th round), HK$66.7 million was granted for carrying out of further translational research, including multicenter clinical trials in the coming five years. The collaborative research was also granted an aggregate amount of HK$ 5.99 million by the Innovation and Technology Commission (“ITC“) for early-stage pre-clinical studies under the University and Industry Collaboration Program (“UICP“).

Prof. Zhiwei CHEN PhD, Founding Director of HKU AIDS Institute, Tenured Professor and Chair of Immunology and Immunotherapy in the Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, the University of Hong Kong (HKU), and Suen Chi-Sun Professor in Clinical Science, inventor of the patented PD-1 Enhanced DNA vaccine technology and the Principal Scientific Advisor of Immuno Cure, said “The Phase I Trial preliminary data demonstrated satisfying safety and immunogenicity profiles of ICVAX in PLWH. It is encouraging to discover that ICVAX enhances functional T cells previously found in EC for HIV-1 suppression. Our team members are very grateful for the significant amount of funding from RGC and ITC, which have enabled us to accomplish our interim achievements at this stage and to further expand our translational research, including an upcoming Phase II clinical trial for the benefit of more and more PLWH.”

Immuno Cure was granted a maximum amount of ΗΚ$8 million funding for this Phase I Trial under the Clinical Translational Catalyst (“CTC“) programme of the Institute for Translational Research (“ITR“) of the Hong Kong Science and Technology Parks Corporation (“HKSTP“). The CTC program is a highly specialized platform to provide all-round support to biomedical companies in the pre-clinical and early clinical stages, aiming to transform Hong Kong and the Greater Bay Area to become the go-to destination for translational medicine in the region. Under this program, funding support will be provided to biomedical companies of HKSTP to bring innovative, life-changing therapies and technologies to patients.

Ms. Gracie Ng, Chief of Staff and Acting Chief Corporate Development Officer, HKSTP said, “The HKSTP team was thrilled to hear the news that Immuno Cure has completed Phase 1 clinical trial for ICVAX. This pioneering vaccine represents a major advancement in our fight against HIV/AIDS. The success highlights our role as one of the global leaders in translational development, producing innovative therapies to improve patients’ quality of life.”

The Hong Kong AIDS Foundation, established in 1991, is a non-governmental social service organization with a mission to limit the spread of HIV infection in the community. Throughout the years, the Foundation has been actively engaged in the promotion of AIDS education, the provision of services, and the nurturing of a harmonious and caring environment for those infected with or affected by HIV/AIDS.

Dr. Che Hung LEONG MD, PhD, GBM, GBS, JP, President of Hong Kong AIDS Foundation and the Chairman of the Advisory Board of Immuno Cure said: “It is exciting to see the positive results of ICVAX, Immuno Cure’s therapeutic HIV vaccine, from its Phase I clinical trial. The trial data shows that ICVAX might potentially provide an alternative to ART which would alleviate the burden of drug compliance of patients. These results suggest that we may be on the brink of a breakthrough with a therapy that could enhance the quality of life for many PLWH and provide them a hope for functional cure in the longer term.”

Immuno Cure is communicating with the NMPA for the upcoming multi-centre, double-blinded, placebo-controlled, dose-finding Phase II clinical trial. The trial will aim to evaluate the immunogenicity and efficacy in controlling HIV viral load. It is anticipated to commence in mid-2025.

Dr. Xia JIN MD PhD, CEO of Immuno Cure concludes, “The encouraging outcomes of the Phase I Trial are attributed by fruitful collaboration for over 8 years between Immuno Cure and Prof. Chen of HKU-AIDS Institute, representing a significant milestone of the development of ICVAX. Looking ahead, we shall move on with our BLA application under NMPA’s breakthrough drug regulatory regime after meeting the expected end points of the Phase II clinical trial. The success of development of ICVAX will not only prove the novelty of our DNA vaccine technology platform, but also mark a giant step towards functional cure of HIV/AIDS, and to enable the relief of burden on PLWH and improvement of their quality of life. Lastly, we thank the volunteers for their participation and the doctors and nurses at the Shenzhen Third Hospital trial site, as well as other clinical trial collaborators, CRO, SMO, CMO and clinical laboratories, for their dedication and diligence, for they are the key elements of the smooth completion of this trial. Also, we would like to thank HKSTP, ITC, and RGC for their generous funding support. Next, we plan to launch a cross-border multi-centre Phase II clinical trial in mid-2025, including CUHK Phase 1 Clinical Trial Centre, Shenzhen Third People’s Hospital, Guangzhou Eighth People’s Hospital, etc. Through this trial, we look forward to cooperating with the Greater Bay Area International Clinical Trial Institute (“GBAICTI“), which will soon begin its service to promote advanced biomedical technology research, clinical trials, and applications in Hong Kong and the Greater Bay Area, aiming to jointly develop Hong Kong into an international medical innovation hub.”

Hashtag: #ImmunoCure #醫克生物 #医克生物

The issuer is solely responsible for the content of this announcement.

About Immuno Cure

Immuno Cure is a clinical stage biotechnology group based in the Hong Kong Science Park, focusing on research and development of immunotherapies for cancers, inflammatory and infectious diseases based on its patented PD-1-enhanced DNA vaccine and Anti-Δ42PD1 Antibody platforms.

To learn more about Immuno Cure, please visit:

About The University of Hong Kong and AIDS Institute of HKUMed

The University of Hong Kong (HKU), founded in 1911, is the first and oldest institution of higher education in Hong Kong. HKU has an established worldwide reputation for being a research-led comprehensive university. The AIDS Institute of HKU was established in November 2007 to take HKU in a new strategic direction in fighting this global epidemic and help to make it a leader in the region in AIDS research, education and prevention. Scientists at the AIDS Institute are fully committed to conducting basic and applied research that facilitates the understanding of AIDS pathogenesis and the development of effective AIDS vaccines. Furtherance to the Hong Kong Theme-based Research Scheme entitled “Potentiating Host Immunity for HIV-1 Functional Cure”, the institute is currently leading the second 5-year term research entitled “Sustained cART-free HIV-1 Control by Immunotherapeutic Interventions”.

To learn more about HKU and AIDS Institute of HKU, please visit and

About The Shenzhen Third People’s Hospital

The Shenzhen Third People’s Hospital / The Second Affiliated Hospital of Southern University of Science and Technology was founded in 1985 by the Shenzhen municipal government. It is a grade A tertiary research-oriented hospital characterized by strong specialty and comprehensive medical services. The hospital covers an area of around 198,400 square meters with 223,000 square meters construction area and 2416 hospital beds, including 1008 in negative pressure wards in the emergency campus for infectious diseases. By far, the hospital has become a large, well-equipped clinical and research center of infectious diseases in the Guangdong-Hong Kong-Macau Greater Bay Area offering comprehensive services. Thus, it contributes to the control of infectious disease and major public health emergency and benefits patients in Shenzhen and adjacent areas.

To learn more about Shenzhen Third People’s Hospital, please visit

About Hong Kong Science and Technology Parks Corporation

Hong Kong Science and Technology Parks Corporation (HKSTP) was established in 2001 to create a thriving I&T ecosystem grooming 13 unicorns, more than 15,000 research professionals and over 2,000 technology companies from 26 countries and regions focused on developing healthtech, AI and robotics, fintech and smart city technologies, etc.

Our growing innovation ecosystem offers comprehensive support to attract and nurture talent, accelerate and commercialise innovation for technology ventures, with the I&T journey built around our key locations of Hong Kong Science Park in Pak Shek Kok, InnoCentre in Kowloon Tong and three modern InnoParks in Tai Po, Tseung Kwan O and Yuen Long realising a vision of new industrialisation for Hong Kong, where sectors including advanced manufacturing, micro-electronics and biotechnology are being reimagined.

Hong Kong Science Park Shenzhen Branch in Futian, Shenzhen plays positive roles in connecting the world and the mainland with our proximity, strengthening cross-border exchange to bring advantages in attracting global talent and allowing possibilities for the development of technology companies in seven key areas: Medtech, big data and AI, robotics, new materials, microelectronics, fintech and sustainability, with both dry and wet laboratories, co-working space, conference and exhibition facilities, and more.

Through our R&D infrastructure, startup support and enterprise services, commercialisation and investment expertise, partnership networks and talent traction, HKSTP continues contribute in establishing I&T as a pillar of growth for Hong Kong.

More information about HKSTP is available at .

About Hong Kong AIDS Foundation Limited

The Hong Kong AIDS Foundation was established in 1991 and is a non-governmental social service organisation. The Foundation’s mission is to limit the spread of HIV infection in the community. Throughout the years, the Foundation has been actively engaged in the promotion of AIDS education, the provision of services, and the nurturing of a harmonious and caring environment for those infected with or affected by HIV/AIDS.

To learn more about Hong Kong AIDS Foundation, please visit .

CamScanner takes ESG to the next level ahead of 2025 with sustainable education and community support

Company’s innovative digital tools demonstrate its commitment to saving paper, supporting higher-education and strengthening communities


NEW YORK, US – Media OutReach Newswire – 12 November 2024 – CamScanner, a global leader in document-scanning apps with over 300 million users, ramped up its ESG initiatives ahead of 2025 to focus on global sustainability and supporting higher-education through the company’s innovative management tools for digital documents.

CamScanner takes ESG to the next level ahead of 2025 with sustainable education and community support

Earlier this year, CamScanner launched the Campus Empowerment Program, a first-of-its-kind initiative aimed at supporting university students and faculty in enhancing their academic lives. This program builds on CamScanner’s longstanding commitment to education, which has already benefited nearly 150,000 university students and thousands of schools across more than 100 countries over the past several years. By making education more accessible, CamScanner ensured that students had the tools necessary to thrive in their studies.

In addition to its work in education, CamScanner promoted social responsibility this year by tackling the technology gap in remote areas. In rural South Sulawesi, Indonesia, where villages often have only one print shop that’s relatively expensive, a local resident uses CamScanner to help her neighbors scan and upload their personal documents from the comfort of their homes. Villagers lauded CamScanner for its ability to produce clean, clear scans with just the tap of a button. This reduces the need to seek out print shops or travel several kilometers to government offices, making it possible for many people who previously lacked the means to apply for social security benefits.

CamScanner’s dedication to being environmentally sustainable also enhanced its impact on education and supporting communities. The company’s #LightsOffScreensOff campaign for Earth Hour 2024 encouraged users to turn off non-essential electronics and reduce paper waste. In 2023 alone, CamScanner’s digital impact contributed to preventing 250,000 tons of carbon emissions, equal to planting about 10 million trees.

“CamScanner has long championed ESG, and we will continue to dedicate ourselves to ESG in the future,” said Kevin Cao General Manager of CamScanner. “We believe sustainable practices and social responsibility are essential for driving positive change and empowering individuals to thrive. 2024 was a fantastic example of that, and 2025 will be even better.”

Follow CamScanner on X, YouTube, and Instagram for our latest updates and campaigns.

Hashtag: #CamScanner

The issuer is solely responsible for the content of this announcement.

Arrow Electronics Brings Engineering and Supply Chain Capabilities for a Broader Ecosystem across GBA


SHENZHEN, CHINA – Media OutReach Newswire – 12 November 2024 – With the theme of “Shaping a smarter and greener tomorrow,” global technology solutions provider Arrow Electronics organized its annual Arrow Technology Showcase event today in Shenzhen, a sci-tech and advanced manufacturing hub in China’s Greater Bay Area (GBA) region.

Arrow Electronics Brings Engineering and Supply Chain Capabilities for a Broader Ecosystem across GBA
Arrow Electronics Brings Engineering and Supply Chain Capabilities for a Broader Ecosystem across GBA

The event featured over 100 innovative products and solutions tailored for edge AI, e-mobility, green energy, and smart industrial and manufacturing applications across various market sectors. The event drew hundreds of technology companies, manufacturers, solution providers, and tech startups from the GBA region.

Industry data forecasts that the Asia-Pacific industrial IoT market to reach US$135 billion by 2030[1]. To support tech companies and startups in accelerating their idea-to-product commercialization journey, Arrow has collaborated with several tech startup incubators in the GBA. These include XbotPark, a global startup incubator focused on robotics and smart hardware, and the Hong Kong Center for Construction Robotics (HKCRC), a scientific research and entrepreneurship platform committed to bringing robotics, automation, and AI technologies into the construction industry to promote its advancement.

Led by Haozhen Li, a project lead at HKCRC, the rebar-tying robot was one of the intelligent construction technology products showcased. This robot, equipped with advanced AI and sensing technologies, can automatically identify and tie rebar nodes, switch tracks, and avoid obstacles. Its enhanced capability to tie nodes in just five seconds with 99.6% accuracy significantly helps improve worker safety, especially for those handling hazardous tasks. The compact design also makes it easy to transport and install in various settings, including infrastructure construction, prefabricated factories, and more.

“I’m thrilled to be involved in the research and development of high-tech projects that utilize robotics and automation technologies. These innovations are driving the transformation of the traditional construction industry from labor-intensive to technology-driven. Thanks to global technology companies like Arrow, aspiring researchers are given entrepreneurial opportunities and support to become entrepreneurs,” said Haozhen Li.

Two other noteworthy innovative products showcased include an IoT-enabled smart flatness meter that digitally assesses the flatness, levelness, and verticality of construction sites, and a handheld LiDAR scanner created by Skyland Innovation, a tech startup committed to merging cutting-edge robotics with advanced 3D reconstruction technologies.

“As we enhance our robotic product offerings and scale up our business, we are excited to be able to access Arrow’s advanced electronic components, design engineering resources, and go-to-market support. With the support of HKCRC and global technology companies like Arrow, we can leverage ecosystem resources to reach a broader market and maximize our growth potential with our advanced robotics and 3D reconstruction technology solutions,” said Jie Pan, CEO of Skyland Innovation.

Autonomous and intelligent devices are transforming the smart manufacturing industry by enhancing efficiency, productivity, and safety. These devices, showcased at the event, feature smart power management, advanced motor control, and AI-imaging technologies, allowing them to perform complex tasks with minimal human intervention. Additionally, AI-powered systems are employed for predictive maintenance, quality control, and real-time data analysis, enabling manufacturers to make informed decisions and improve overall operational efficiency.

The event also highlighted various mobility and electrification solutions, including battery management systems , matrix headlamps, interior lighting, automotive MCU boards, gateways and clusters, ultra-wideband, telematics boxes, traction inverters, and onboard chargers.

“The proliferation of AI-powered technology, increasing industrial automation and digitization, the electrification of everything, and the demand for energy-efficient and miniature devices are driving the demand for semiconductors as well as interconnect, passive, and electromechanical components,” said Jacqueline Leung, Arrow’s president for its Greater China components business. “We recognize that engineering resources and capabilities are essential for startups and innovators to maximize their business potential. We are committed to continuing our collaboration with tech incubation communities such as XbotPark and HKCRC to empower innovators and entrepreneurs to overcome technological and supply chain challenges and bring their impactful and innovative ideas to market faster.”

To learn more about robotics and smart industrial solutions, click here for more information.

[1] https://www.meticulousresearch.com/pressrelease/858/asia-pacific-industrial-iot-market-2030

Hashtag: #ArrowElectronics




Wechat: arrow-cn

The issuer is solely responsible for the content of this announcement.

About Arrow Electronics

Arrow Electronics (NYSE:ARW) sources and engineers technology solutions for thousands of leading manufacturers and service providers. With global 2023 sales of $33 billion, Arrow’s portfolio enables technology across major industries and markets. Learn more at arrow.com.

Kwoon Chung Bus x YAS – Groundbreaking Cross-Border Embedded Insurance for a Seamless Travel Experience Between Hong Kong and Mainland China


HONG KONG SAR – Media OutReach Newswire – 12 November 2024 – Kwoon Chung Bus has partnered with YAS, an InsurTech pioneer, to launch Hong Kong’s first embedded travel insurance specifically designed for cross-border bus trips. This partnership introduces a seamless, embedded travel insurance for the millions of passengers who cross the Hong Kong-Mainland China border each year. With this new integration, YAS and Kwoon Chung are transforming cross-border travel with enhanced safety and peace of mind.

Kwoon Chung Bus has partnered with YAS, an InsurTech pioneer, to launch Hong Kong's first embedded travel insurance specifically designed for cross-border bus trips. (From right) Mr. William Lee, Co-founder of YAS, Mr. Adrian Leung, Director of ZAKC Limited, Mr. Andy Ann, Co-founder of YAS, and Mr. Timothy Wong, COO of Kwoon Chung Group
Kwoon Chung Bus has partnered with YAS, an InsurTech pioneer, to launch Hong Kong’s first embedded travel insurance specifically designed for cross-border bus trips. (From right) Mr. William Lee, Co-founder of YAS, Mr. Adrian Leung, Director of ZAKC Limited, Mr. Andy Ann, Co-founder of YAS, and Mr. Timothy Wong, COO of Kwoon Chung Group

In collaboration with renowned retailers and ecosystem partners, YAS goes beyond insurance to offer travellers an enhanced overall travel experience with a range of shopping discounts, fostering cross-border tourism and supporting Hong Kong and Greater Bay Area development.

Embedded Insurance for Peace of Mind

Kwoon Chung Bus customers who purchase memberships or points via the “Hong Kong-Mainland Express” WeChat Mini Program will receive complimentary embedded travel protection from YAS for their initial journey. YAS Co-Founder, Mr. William Lee, stated, “At YAS, our mission is to provide the fastest, simplest embedded insurance experience, empowering fellow citizens to start their journeys with peace of mind. This collaboration with Kwoon Chung marks just the beginning of a new era in cross-border travel, and we are dedicated to driving further innovation to crown Hong Kong as the global insurance pioneer, making insurance smarter, more accessible, and more convenient”. YAS is proud to partner with Generali Hong Kong once again to deliver this industry-leading insurance program.

Collaborating with Retail Partners for an Unmatched Shopping Experience

To elevate the travel experience, YAS x Kwoon Chung is introducing the “Double Delight” benefits for members. In partnership with notable retailers, including Maxim’s, Kee Wah Bakery, Catalo, Hang Lung Properties, and the hello Hang Lung Malls Rewards Program, members of the Kwoon Chung bus enjoy shopping discounts at over 50 outlets across Hong Kong Island, Kowloon, and the New Territories. Travellers can disembark at various locations to explore the vibrant city and enjoy an exciting shopping experience.

Driving Tourism Growth in the Greater Bay Area with Future Prospects

This collaboration represents an innovative first in cross-border bus service, both Kwoon Chung Bus and YAS look forward to future partnerships to drive tourism development in the Greater Bay Area. Mr. Timothy Wong, COO of Kwoon Chung Group, expressed his enthusiasm, stating, “YAS’s embedded travel insurance not only offers travellers valuable protection but enhances their safety and convenience. We look forward to supporting Greater Bay Area tourism, creating a superior travel experience for all”.

Insurance Coverage Overview:

Accidental Medical Expenses

  • Adults (18-79): Up to HK$5,000
  • Children (Under 18) and Seniors (80+): Up to HK$2,500
  • Therapy, Acupuncture & Dental (Medically Necessary): HK$200/day
  • Deductible: HK$500 per incident

Personal Belongings

  • Documents & Baggage (e.g., phones, laptops, tablets, cameras): Up to HK$10,000
  • Limit per Item: HK$1,000
  • Deductible: HK$500 per incident

Accidental Death or Permanent Disability

  • Adults (18-79): Up to HK$200,000
  • Children (Under 18) and Seniors (80+): Up to HK$100,000

Terms and conditions apply. Learn more: https://membership.yas.io/zh/kc/campaign_gbt/
Hashtag: #KwoonChungBus #YAS

The issuer is solely responsible for the content of this announcement.

About YAS

YAS is an award winning InsurTech company in Asia, leveraging cutting-edge AI and blockchain technology to deliver dynamic, on-demand insurance solutions. YAS (IA License Number FA2648) is a registered insurance agency in Hong Kong, distributing general insurance products under the Insurance Companies Ordinance (Chapter 41 of the Laws of Hong Kong). For more information, visit .

About Kwoon Chung Bus

Founded in 1948 by the late Mr. Kwoon Chung Wong, Kwoon Chung Bus Holdings Limited has grown to become the largest non-franchised bus and luxury coach operator in Hong Kong. The group was listed on the Main Board of the Hong Kong Stock Exchange in 1996 and currently operates approximately 1,285 non-franchised public buses and 428 luxury coaches as of March 31, 2024.

About Assicurazioni Generali S.p.A

In 1981, Assicurazioni Generali S.p.A was first registered as an authorised insurer in Hong Kong, with the business extending into the life insurance sector in 2016 with Generali Life (Hong Kong) Limited. With a combination of local knowledge and Generali Group’s global expertise, we develop unique and innovative life insurance, general insurance, speciality insurance, and employee benefits solutions to meet the needs of our customers.

About ZAKC Limited

ZAKC Limited is a joint venture company established by Kwun Chung Bus and Zhong An, committed to providing customers with an online service platform for Guangdong-Hong Kong-Macao cross-border transportation, established in 2019 and located in Hong Kong S.A.R..

Double Delight Membership Offer

From November 8 to December 8, Hong Kong-Mainland Express members can purchase the Double Delight offer for a special promotion half-price at $19, receiving first-trip travel insurance and retail discounts.

Insurance coverage is underwritten by Generali Hong Kong and arranged by YAS Digital Limited (“YAS”) (IA License Number FA2648). Kwoon Chung Bus is not an intermediary or insurance agent of Generali or any other licensed insurance company.